Oral contraceptives and venous thrombosis: different sensitivities to activated protein C in women using second‐ and third‐generation oral contraceptives

Epidemiological studies have shown that women who use third‐generation oral contraceptives (OC) containing desogestrel, gestodene or norgestimate have a higher risk of venous thrombosis than women who use second‐generation OC containing levonorgestrel. It is also known that a mutation in factor V (factor VLeiden), which results in resistance to activated protein C (APC) and which is the most common cause of hereditary thrombophilia, potentiates the prothrombotic effect of OC.

[1]  B. Dahlbäck,et al.  Resistance to activated protein C as a basis for venous thrombosis. , 1994, The New England journal of medicine.

[2]  S. Daeschner.  Pulmonary embolism. , 1988, Nursing.

[3]  R. Bertina,et al.  Laboratory Diagnosis of APC-Resistance: A Critical Evaluation of the Test and the Development of Diagnostic Criteria , 1994, Thrombosis and Haemostasis.

[4]  B. Dahlbäck,et al.  Familial thrombophilia due to a previously unrecognized mechanism characterized by poor anticoagulant response to activated protein C: prediction of a cofactor to activated protein C. , 1993, Proceedings of the National Academy of Sciences of the United States of America.

[5]  J. Griffin,et al.  Deficiency of protein C in congenital thrombotic disease. , 1981, The Journal of clinical investigation.

[6]  Pieter H. Reitsma,et al.  Mutation in blood coagulation factor V associated with resistance to activated protein C , 1994, Nature.

[7]  T. Farley,et al.  Venous thromboembolic disease and combined oral contraceptives: results of international multicentre case-control study. World Health Organization Collaborative Study of Cardiovascular Disease and Steroid Hormone Contraception. , 1995, Lancet.

[8]  C. Esmon,et al.  The roles of protein C and thrombomodulin in the regulation of blood coagulation. , 1984, The Journal of biological chemistry.

[9]  J. Griffin,et al.  Plasma protein S deficiency in familial thrombotic disease. , 1984, Blood.

[10]  P. Reitsma,et al.  Increased Risk of Venous Thrombosis in Oral-Contraceptive Users Who Are Carriers of Factor V Leiden Mutation , 1995 .

[11]  J. Hirsh,et al.  Congenital antithrombin III deficiency. Incidence and clinical features. , 1989, The American journal of medicine.

[12]  D. Girelli,et al.  Resistance to activated protein C in healthy women taking oral contraceptives , 1995, British journal of haematology.

[13]  J. Griffin,et al.  Anticoagulant protein C pathway defective in majority of thrombophilic patients. , 1993, Blood.

[14]  F. Preston,et al.  Rapid two-stage PCR for detecting factor V G1691A mutation , 1994, The Lancet.

[15]  S. Béguin,et al.  A New Assay Based on Thrombin Generation Inhibition to Detect Both Protein C and Protein S Deficiencies in Plasma , 1994, Thrombosis and Haemostasis.

[16]  A. Decherney,et al.  EVALUATION OF A NEW GENERATION OF ORAL CONTRACEPTIVES , 1993, Obstetrics and gynecology.

[17]  H C Hemker,et al.  Thrombin Generation in Plasma: Its Assessment Via the Endogenous Thrombin Potential , 1995, Thrombosis and Haemostasis.

[18]  W. Spitzer,et al.  Third generation oral contraceptives and risk of venous thromboembolic disorders: an international case-control study , 1996, BMJ.

[19]  Douglas G. Altman,et al.  Practical statistics for medical research , 1990 .

[20]  J. van der Meer,et al.  Sensitivity to Activated Protein C; Influence of Oral Contraceptives and Sex , 1995, Thrombosis and Haemostasis.

[21]  H. Hemker,et al.  A Computer Assisted Method to Obtain the Prothrombin Activation Velocity in Whole Plasma Independent of Thrombin Decay Processes , 1986, Thrombosis and Haemostasis.

[22]  J. Vandenbroucke,et al.  Enhancement by factor V Leiden mutation of risk of deep-vein thrombosis associated with oral contraceptives containing a third-generation progestagen , 1995, The Lancet.

[23]  F. Rosendaal,et al.  Venous thrombosis due to poor anticoagulant response to activated protein C: Leiden Thrombophilia Study , 1993, The Lancet.

[24]  H. Hemker,et al.  Peptide Bond Cleavages and Loss of Functional Activity during Inactivation of Factor Va and Factor VaR506Q by Activated Protein C (*) , 1995, The Journal of Biological Chemistry.

[25]  T W Meade,et al.  Haemostasis and thrombosis. , 1978, International journal of epidemiology.

[26]  J. Newton.  Classification and comparison of oral contraceptives containing new generation progestogens. , 1995, Human reproduction update.

[27]  P. Reitsma,et al.  High risk of thrombosis in patients homozygous for factor V Leiden (activated protein C resistance) , 1995, Blood.